By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NovaDigm Therapeutics  

4201 James Ray Drive
REAC 1 Building, Suite 2200
Grand Forks  North Dakota  58202  U.S.A.
Phone: 701-757-5161 Fax: 701-335-7121



Company News
NovaDigm Therapeutics Announces Positive Results From First-Ever Antifungal Immunotherapy In A Phase 2a Study In Women With Recurrent Vulvovaginal Candidiasis (RVVC) 8/15/2016 11:49:46 AM
NovaDigm Therapeutics ’ Chief Executive Officer, Timothy Cooke, Appointed To The National Vaccine Advisory Committee 11/3/2015 11:08:39 AM
NovaDigm Therapeutics Strengthens Candida Vaccine Portfolio With Three New Antigens Via Series Of Rights Acquisitions 6/10/2014 10:13:30 AM
NovaDigm Therapeutics Raises $14 Million Series B to Support Phase 2 Trial of NDV-3 Vaccine Against Candida 10/3/2013 7:14:56 AM
NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC) 9/26/2013 9:55:58 AM
Results From Positive Phase 1 Study of NovaDigm Therapeutics ’ NDV-3 Vaccine for Candida and Staph Infections Published in Vaccine 12/13/2012 10:12:39 AM
Pfizer Inc. (PFE), GlaxoSmithKline (GSK) and NovaDigm Therapeutics ' Vaccine for Staph More Lethal Than Skin Cancer Tested 9/17/2012 8:01:15 AM
NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine 5/7/2012 9:52:42 AM
NovaDigm Therapeutics Presents Positive Preclinical Data in Vulvovaginal Candidiasis for NDV-3 Vaccine 9/19/2011 7:16:53 AM
NovaDigm Therapeutics to Present Positive Clinical and Preclinical Data for NDV-3 Vaccine at ICAAC 9/12/2011 10:20:04 AM